Neuromyélite optique de Devic chez l'enfant: à propos de 1 cas, avec revue de la littérature

Djemal, N.; Salah, Mohamed Ben; Hlima, N. Ben; Rhomdhane, W. Ben; Ammar, H. Ben; Chaâbouni, M; Chouchane, C.; Karray, A.

doi:10.1016/j.arcped.2007.08.004

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were close to those found in several studies [7,8,10,11,12]. The Highlighting in our patients of oligoclonal IgG profile with intrathecal IgG synthesis was strongly suggestive of a chronic inflammatory disease of the brain [14].…”

Section: Discussionsupporting

confidence: 79%

Devic Disease in Senegal, a West African Country: About Five Cases

2017

ARC Journal of Neuroscience

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

Devic Disease in Senegal, a West African Country: About Five Cases

2017

ARC Journal of Neuroscience

View full text Add to dashboard Cite

“…At present, the mainstay of therapy is the treatment of acute attacks, prevention of medical complications, and rehabilitation. Specific medications that have been used include: methylprednisolone with prednisone taper, immunosuppressants such as azathioprine [7, 8], cyclophosphamide [8, 9], and rituximab [10, 11], and plasmapheresis [12–15]. Rituximab is a murine/human monoclonal antibody directed against CD20 that induces B-cell depletion when administered in vivo.…”

Section: Discussionmentioning

confidence: 99%

Neuromyelitis Optica in Child: Diagnostic and Therapeutic Challenges

Dembinski

Gieron-Korthals

Martinez

et al. 2013

Case Reports in Pediatrics

View full text Add to dashboard Cite

Neuromyelitis optica (NMO) is a rare syndrome of severe inflammatory demyelination of the central nervous system, causing attacks of optic neuritis and transverse myelitis. Although uncommon, attention should be given to the proper identification and management of the affected patients. We present a case of a 13-year-old girl with severe neuromyelitis optica. The patient's initial presentation consisted of encephalopathy and optic neuritis. Approximately 2 months later, coinciding with the weaning of steroid treatment, she presented with ascending paralysis and respiratory failure. She was seropositive for NMO-IgG. Treatment included intravenous immune globulin, steroids, plasmapheresis, and rituximab and was complemented with proper nutrition, vitamins, minerals, and intense rehabilitation. Two years after the initial presentation and one short relapse, the patient has made a remarkable recovery without neurologic deficit. This report underscores the difficulty in making the initial diagnosis, choosing the best treatment, and the need for more streamlined pediatric guidelines for diagnosis, treatment, and prevention of relapses of pediatric NMO.

show abstract

Treatment of Pediatric Optic Neuritis

Bonhomme

Mitchell

2011

Curr Treat Options Neurol

View full text Add to dashboard Cite

Pediatric optic neuritis is a rare disorder causing a subacute loss of vision (often bilateral) in children, often of a severe degree. Common clinical findings include dense visual field loss, afferent pupillary defect (APD) in unilateral cases, and papillitis that is often bilateral. Contrary to optic neuritis in the adult population, the differential diagnosis for this disorder in pediatric patients is quite extensive, so neuroimaging and serologic evaluation are necessary to exclude an infectious or neoplastic process. Pediatric optic neuritis may occur as a clinically isolated syndrome, or in association with diffuse neurologic dysfunction, such as acute disseminated encephalomyelitis (ADEM). Optic neuritis may also be the first episode heralding the onset of pediatric multiple sclerosis or neuromyelitis optica (NMO or Devic's disease). Therefore, formal neurologic evaluation and follow-up are indicated. Although the management of this disorder in adults is well described, there is a paucity of evidence-based, prospective clinical data on its management and treatment in a pediatric population. The current treatment of pediatric optic neuritis consists of 3 to 5 days of intravenous methylprednisolone (4-30 mg/kg per day), followed by a prolonged oral corticosteroid taper. A prolonged course of oral steroid (2-4 weeks) is recommended to avoid recurrence, which is common in this age group. Some controversy persists concerning the exposure of children to high-dose parenteral corticosteroids to treat an entity that is usually self-limited, but given the severity of vision loss in one or both eyes in this population, this intervention is standard in neuro-ophthalmologic practice.

show abstract

Neuromyélite optique de Devic chez l'enfant: à propos de 1 cas, avec revue de la littérature

Cited by 4 publications

References 9 publications

Devic Disease in Senegal, a West African Country: About Five Cases

Devic Disease in Senegal, a West African Country: About Five Cases

Neuromyelitis Optica in Child: Diagnostic and Therapeutic Challenges

Treatment of Pediatric Optic Neuritis

Contact Info

Product

Resources

About